| HOME >> BIOLOGY >> TECHNOLOGY |
ating right effect of RMB0.02. Basic and diluted earnings per ordinary share for the first quarter of fiscal 2013 were RMB0.41 ($0.06).
LIQUIDITY. As of June 30, 2012, the Company had cash and cash equivalents of RMB1,146.7 million ($180.5 million) compared to RMB794.3 million as of March 31, 2012. The Company had total debt of RMB416.4 million ($65.5 million) as of June 30, 2012. Operating cash flow for the quarter amounted to RMB136.9 million ($21.5 million).
Ms. Zheng concluded, "Our Guangdong operation continues to deliver impressive performance. In order to sustain momentum in this highly promising market, we are expanding our operations there with a new facility. We anticipate that it will commence operating in two years and will be able to provide a platform for next-stage growth. As we increase our capacity in Guangdong, we will also acquire a minority interest in Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd., the Company's operating arm in Guangdong province from Cordlife. This is pursuant to our recently announced alliance-building transactions. Upon completion of the announced transactions, Cordlife will become an affiliate of our group by holding approximately 10% equity interest in CCBC. This strategic alliance represents immense value for our existing shareholders as we can develop a strategic presence throughout Asia and benefit from Cordlife's Asia-wide expertise to better serve existing and prospective customers."
[2] "Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant
'/>"/>
| SOURCE China Cord Blood Corporation Copyright©2012 PR Newswire. All rights reserved |
Related biology technology :
1. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
2. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
3. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
4. China Cord Blood Corporation Files its Annual Report on Form 20-F
5. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
6. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
7. China Cord Blood Corporation Continues Share Repurchase Program
8. Journal of Renewable and Sustainable Energy highlights energy trends in China
9. WuXi PharmaTech Named a Top Ten Outsourcing Enterprise in China for Five Consecutive Years
10. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
11. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |